Literature DB >> 10094262

Language outcome following multiple subpial transection for Landau-Kleffner syndrome.

C L Grote1, P Van Slyke, J A Hoeppner.   

Abstract

Landau-Kleffner syndrome is an acquired epileptic aphasia occurring in normal children who lose previously acquired speech and language abilities. Although some children recover some of these abilities, many children with Landau-Kleffner syndrome have significant language impairments that persist. Multiple subpial transection is a surgical technique that has been proposed as an appropriate treatment for Landau-Kleffner syndrome in that it is designed to eliminate the capacity of cortical tissue to generate seizures or subclinical epileptiform activity, while preserving the cortical functions subserved by that tissue. We report on the speech and language outcome of 14 children who underwent multiple subpial transection for treatment of Landau-Kleffner syndrome. Eleven children demonstrated significant postoperative improvement on measures of receptive or expressive vocabulary. Results indicate that early diagnosis and treatment optimize outcome, and that gains in language function are most likely to be seen years, rather than months, after surgery. Since an appropriate control group was not available, and that the best predictor of postoperative improvements in language function was that of length of time since surgery, these data might best be used as a benchmark against other Landau-Kleffner syndrome outcome studies. We conclude that multiple subpial transection may be useful in allowing for a restoration of speech and language abilities in children diagnosed with Landau-Kleffner syndrome.

Entities:  

Mesh:

Year:  1999        PMID: 10094262     DOI: 10.1093/brain/122.3.561

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  10 in total

1.  Landau-Kleffner Syndrome.

Authors:  Andres M. Kanner
Journal:  Epilepsy Curr       Date:  2001-11       Impact factor: 7.500

Review 2.  Management of Landau-Kleffner syndrome.

Authors:  Mohamad A Mikati; Alhan N Shamseddine
Journal:  Paediatr Drugs       Date:  2005       Impact factor: 3.022

Review 3.  Treatment of Epileptic Encephalopathies: Current State of the Art.

Authors:  Hiroki Nariai; Susan Duberstein; Shlomo Shinnar
Journal:  J Child Neurol       Date:  2017-01-30       Impact factor: 1.987

Review 4.  Multiple subpial transections in pediatric epilepsy: indications and outcomes.

Authors:  Mony Benifla; Hiroshi Otsubo; Ayako Ochi; O Carter Snead; James T Rutka
Journal:  Childs Nerv Syst       Date:  2006-06-20       Impact factor: 1.475

Review 5.  Neurosurgical approaches to pediatric epilepsy: Indications, techniques, and outcomes of common surgical procedures.

Authors:  Jonathan Dallas; Dario J Englot; Robert P Naftel
Journal:  Seizure       Date:  2018-11-16       Impact factor: 3.184

6.  Landau-Kleffner syndrome: an uncommon dealt with case in Southeast Asia.

Authors:  Naresh Motwani; Suhaim Afsar; Nachiket S Dixit; Nitin Sharma
Journal:  BMJ Case Rep       Date:  2015-09-29

Review 7.  What is more harmful, seizures or epileptic EEG abnormalities? Is there any clinical data?

Authors:  Gregory L Holmes
Journal:  Epileptic Disord       Date:  2014-10       Impact factor: 1.819

8.  Phonological short-term memory networks following recovery from Landau and Kleffner syndrome.

Authors:  Steve Majerus; Steven Laureys; Fabienne Collette; Guy Del Fiore; Christian Degueldre; André Luxen; Martial Van der Linden; Pierre Maquet; Marie-Noëlle Metz-Lutz
Journal:  Hum Brain Mapp       Date:  2003-07       Impact factor: 5.038

Review 9.  Present status of surgical intervention for children with intractable seizures.

Authors:  Dewi T Depositario-Cabacar; James J Riviello; Masanori Takeoka
Journal:  Curr Neurol Neurosci Rep       Date:  2008-03       Impact factor: 5.081

Review 10.  Surgical treatment of pediatric epileptic encephalopathies.

Authors:  J Fridley; G Reddy; D Curry; S Agadi
Journal:  Epilepsy Res Treat       Date:  2013-10-30
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.